China Pharma Holdings (CPHI) Non-Current Assets (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Non-Current Assets came in at $43.1 million in Q1 2026, up 279.55% YoY from $11.4 million in Q1 2025, and up 50.56% on a QoQ basis from $28.7 million in Q4 2025.
China Pharma Holdings (CPHI) Non-Current Assets (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Non-Current Assets data on file, last reported at $43.1 million in Q1 2026.
- Quarterly Non-Current Assets rose 279.55% year-over-year to $43.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.3 million (up 124.04% YoY) and the FY2025 annual result came in at $28.7 million, up 146.64% from the prior year.
- Non-Current Assets improved to $43.1 million in Q1 2026, from $28.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $43.1 million in Q1 2026 to a low of $9.5 million in Q3 2023.
- A 5-year average of $14.0 million and a median of $11.3 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets dropped 24.53% — and 2026, when it soared 279.55%.
- Tracing CPHI's Non-Current Assets over 5 years: stood at $11.8 million in 2022, then declined by 11.4% to $10.5 million in 2023, then climbed by 10.93% to $11.6 million in 2024, then jumped by 146.64% to $28.7 million in 2025, then soared by 50.56% to $43.1 million in 2026.
- The last three Non-Current Assets figures came in at $43.1 million (Q1 2026), $28.7 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 2.96 Bn |
| 10 | China Pharma Holdings | 42.35 Mn | 42.04 Mn | 83,566.00 | 42.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.14 Mn |
| Dec 31, 2025 | 28.65 Mn |
| Sep 30, 2025 | 13.48 Mn |
| Jun 30, 2025 | 11.07 Mn |
| Mar 31, 2025 | 11.37 Mn |
| Dec 31, 2024 | 11.62 Mn |
| Sep 30, 2024 | 9.73 Mn |
| Jun 30, 2024 | 10.29 Mn |
| Mar 31, 2024 | 11.07 Mn |
| Dec 31, 2023 | 10.47 Mn |
| Sep 30, 2023 | 9.55 Mn |
| Jun 30, 2023 | 10.18 Mn |
| Mar 31, 2023 | 11.28 Mn |
| Dec 31, 2022 | 11.82 Mn |
| Sep 30, 2022 | 10.60 Mn |
| Jun 30, 2022 | 11.66 Mn |
| Mar 31, 2022 | 12.88 Mn |
| Dec 31, 2021 | 13.56 Mn |
| Sep 30, 2021 | 14.04 Mn |
| Jun 30, 2021 | 14.68 Mn |